Kras mutation is a marker of worse oncologic outcomes after percutaneous radiofrequency ablation of colorectal liver metastases

Abstract

BACKGROUND Kras mutation has been associated with shorter overall survival and time to disease recurrence after resection of colorectal liver metastases (CLM). This study evaluated the prognostic value of Kras mutation in patients with CLM treated by percutaneous radiofrequency ablation (RFA). METHODS This is an IRB waived retrospective analysis of the… (More)
DOI: 10.18632/oncotarget.19806

Topics

8 Figures and Tables

Cite this paper

@inproceedings{Shady2017KrasMI, title={Kras mutation is a marker of worse oncologic outcomes after percutaneous radiofrequency ablation of colorectal liver metastases}, author={Waleed Shady and Elena Nadia Petre and Efsevia Vakiani and Etay Ziv and Mithat Gonen and Karen T. Brown and Nancy E. Kemeny and Stephen B. Solomon and David B. Solit and Constantinos T. Sofocleous}, booktitle={Oncotarget}, year={2017} }